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Background: This study was designed to evaluate the effectiveness of radiofrequency ablation in patients with
intermediate (BCLC B) stage hepatocellular carcinoma who underwent transcatheter arterial chemoembolization.
Methods: Included in this study were 211 patients with intermediate stage HCC who underwent initial transcatheter
arterial chemoembolization and were potentially amendable for radiofrequency ablation (single tumor with diameter
5-8 cm, median 6.0 cm; 2–5 multiple nodules with diameter less than 5 cm) between January 2005 and December
2011. According to the inclusion and exclusion criteria, 55 patients were treated with following radiofrequency ablation,
and the remaining 156 patients were treated with transcatheter arterial chemoembolization alone. The treatment
effectiveness, local tumor control and survival outcome between the two groups were compared.
Results: The complete tumor necrosis rate after treatment was 76.9% in combination group vs. 46.5% in transcatheter
arterial chemoembolization alone group (P = 0.02). The major complication rate was 1.8% in combination group vs. 2.6%
in transcatheter arterial chemoembolization alone group. Follow-up observation showed that the total tumor control rate
was 74.5% in combination group versus 54.5% in transcatheter arterial chemoembolization alone group (P < 0.001). The
1-, 3- and 5-year survival rates in combination group were significantly higher than those in TACE alone group (P = 0.01).
Conclusions: Radiofrequency ablation following initial transcatheter arterial chemoembolization delays tumor progression
and prolongs overall survival of patients with intermediate stage HCC tumors.
Keywords: Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Radiofrequency ablation, Combination
therapy, SurvivalBackground
Hepatocellular carcinoma (HCC) is the 6th most com-
mon cancer worldwide [1]. Surgical resection and liver
transplantation are the current mainstays in the treat-
ment of HCC patients. Unfortunately, only about 20%
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unless otherwise stated.surgical therapy is the only option currently available for
most patients with intermediate or advanced HCC.
According to the Barcelona Clinic Liver Cancer (BCLC)
guideline, radiofrequency ablation (RFA) or surgical resec-
tion is only indicated for patients with early stage (BCLC
stage A) HCC, and transcatheter arterial chemoemboliza-
tion (TACE) is the first-line treatment for patients with
intermediate (BCLC stage B) HCC [3,4]. Although it has
been reported [5-7] that chemotherapy combined with
ischemic necrosis induced by arterial embolization could
delay tumor progression and improve patient overall. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion completely by TACE alone. Extracapsular or intrahe-
patic tumor invasion is likely to occur after TACE due to
incomplete embolization. In addition, TACE may poten-
tially cause hypoxia within the tumors, and ischemic injury
after TACE could induce the up-regulation of vascular
endothelial growth factor (VEGF) [8], which may favor
HCC growth, invasion and metastasis. Therefore, new
strategies are needed to improve the outcome of patients
with intermediate HCC who undergo TACE treatment.
RFA has emerged as a new curative treatment owing
to its safety and effectiveness for early-stage small HCC
[9-12]. In comparison with TACE, the advantage of RFA
is curative local control of small HCC, but it is less
favorable for complete tumor necrosis of tumors larger
than 5 cm [13]. The combination of TACE and RFA has
several advantages over RFA or TACE alone. First, as a
downstage treatment, TACE can reduce tumor burden,
decrease viable tumor volume before RFA, thus increas-
ing the ablation rates of large tumors. Second, after
TACE or repeated TACE procedures, the main artery
supplying the tumor may be narrowed or even be oc-
cluded, and snaking arterioles may be regenerated from
the phrenic, intercostal, gastric and superior mesenteric
arteries [14], making it difficult to selectively catheterize
the feeding artery to control residual tumor cells. While
subsequent RFA can directly ablate the refractory tumors.
Third, it is generally believed that recurrences after cura-
tive treatment for HCC in the early post-treatment period
arise, not because of incomplete treatment of the primary
tumor but because of pre-existing microscopic tumor foci
that are not detected by imaging modalities [15]. TACE
can target undetected these satellite lesions surrounding
the main tumor, label the range and size of the tumor, thus
providing guidance for RFA [16]. TACE combined with
RFA has been reported to be effective for local control of
medium-sized HCC tumors (3-5 cm) [17]. However,
whether such combination therapy could provide thera-
peutic benefits to intermediate HCC unsuitable for RFA
monotherapy has not been clarified. The purpose of this
study was to evaluate the effectiveness and survival benefit
of the TACE+RFA approach to the management of inter-
mediate HCC.
Methods
Patients and enrollment criteria
From January 2005 to December 2011, 747 patients with
intermediate (BCLC B) HCC received first-line TACE
treatment at the Liver Cancer Institute of Fudan University
Zhongshan Hospital (Shanghai, China). The diagnosis of
HCC was confirmed pathologically or clinically according
to the AASLD criteria [18]. Before TACE treatment,
patients were primarily evaluated by experienced surgeons
and were excluded the possibility of liver resection ortransplantation. After initial TACE treatment (1–5 ses-
sions), 211 patients who were potential candidates for sub-
sequent RFA were further evaluated and included into this
study based on the inclusion criteria: 1) the presence of a
single HCC tumor ≤8 cm in diameter, or multi-nodular
HCC tumors (n ≤ 5) small than 5 cm in diameter before
initial TACE; 2) the presence of viable residual HCC with
retained iodized oil after TACE as shown by the follow-up
liver CT and/or MRI scan;3) the absence of portal vein in-
vasion and extrahepatic metastasis; and 4) Child-Pugh class
A or B. Of the 211 patients, 55 patients received combined
RFA treatment based on the following criteria: 1) viable
residual tumors after TACE could be detected by follow-up
ultrasonography 2) residual tumors could be possibly ab-
lated with curative intention by RFA; 3) absence of severe
coagulopathies, such as prothrombin time ≤16 s or platelet
count >50000/mL; and 4) patients who signed informed
consent for RFA. The other 156 patients who were not
suitable for RFA and received repeated TACE treatment
were assigned to TACE alone group based on the following
reasons: 1) tumors were poorly visible on planning ultra-
sound; 2) percutaneous RFA was infeasible due to the
high risk location of thermal injury or could result in in-
complete ablation due to the inadequate electrode path;
3) there existed coagulopathies such as prothrombin
time >16 s or platelet count <50000/mL; and 4) patients
were unwilling to receive additional RFA treatment due
to economic or other personal reasons, although their
residual tumors could be treated with combined RFA.
Treatment effectiveness, local tumor control and sur-
vival outcome of the patients between the two groups
were compared retrospectively. The TACE or RFA treat-
ment procedures were according to our institutional stand-
ard treatment protocol at Fudan University Zhongshan
Hospital. Informed consent was obtained from all patients
and the study protocol was complied with the ethical stan-
dards of the Helsinki Declaration. This study was approved
by the Medical Ethics Committee of Fudan University
Zhongshan Hospital.
Transarterial chemoembolization
TACE was performed as previously described [19].
Briefly, after introduction of a 5 F (Cook©, Bloomington,
USA) or 4 F RH catheter (Cordis ©, CA, USA) using the
Seldinger technique through the femoral artery, an angio-
graphic survey of the abdominal vessels was performed.
Depending on the size, location and arterial supply of the
tumor, the tip of the catheter was advanced toward the
tumor-feeding arteries for selective embolization of all
tumors. Segmental embolization was also performed in
small tumors by using a microcatheter (Terumo©, Tokyo,
Japan) if needed. Oxaliplatin (100–150 mg) and/or 5-
fluorouracil (500–1000 mg) were infused. Epirubicin (30–
60 mg) or Mitomycin C (5–10 mg) mixed with 5-30 ml
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cence. In hypervascular tumors where embolization was
insufficient, gelatin sponge particles or strips were used
for further embolization. The dose of the chemotherapeu-
tic agent and lipiodol and the quantity of embolic material
were determined based on the tumor burden, vascularity
and liver function reverse.
Radiofrequency ablation
After TACE treatment, a dynamic contrast CT or MRI
scan was performed to evaluate the post- TACE tumor
response. Patients who were considered as potential
candidates for RFA were further examined by ultrasound
or contrast ultrasound. Lesions to be ablated should be
clearly visible on ultrasonography with a safe path.
Ablation procedures were conducted in all patients with
curative intention. The details of the treatment proced-
ure were the same as described in our previous study
[20]. Generally, RFA was performed with the patients
under local anesthesia and real-time ultrasonographic
guidance by using the RITA system (RITA Medical
Systems Inc., Mountain View, CA, n = 14) or Cool Tip
system (Valleylab, Boulder, CO, USA, n = 41). Two cycles
(12 min each) were required during RFA. Overlap abla-
tion was allowed to cover the whole tumor nodule to
achieve a sufficiently safe margin of 0.5-1 cm if possible.
Treatment assessment and follow-up observation
After each session of TACE treatment or RFA, a
contrast-enhanced CT or MRI scan in 1–2 months was
performed to evaluate the tumor response and side
effects. In patients with residual viable tumors or incom-
plete ablation in the remaining liver, an additional ses-
sion of TACE or RFA was performed as appropriate.
Patients who showed no evidence of viable tumors were
followed up every 2–3 months for serum alpha-
fetoprotein (AFP), abdomen ultrasonography and chest X-
ray. For patients with test results suggestive of tumor
recurrence, CT and/or MRI were used. Tumor response
was evaluated according to the modified Response Evalu-
ation Criteria in Solid Tumors [21]. Local tumor control
was assessed by the tumor control rate at 6 month after
treatment, and time to tumor progression, which was
defined as the interval from the date of initial treatment
to the date of tumor progression, death or the last
follow-up visit. Overall survival was calculated from the
date of entry into the treatment to the date of death or
the last follow-up.
Statistical analysis
Quantitative data were compared using the Student t
test. Categorical data were analyzed by the chi-square
test or Fisher exact test as appropriate. Survival analysis
was estimated by the Kaplan-Meier survival method andcompared by the log-rank test. Possible prognostic fac-
tors influencing tumor progression and overall survival
were analyzed using a Cox proportional hazards regres-
sion model. Statistical significance was set at P < 0.05
(two sided). All analyses were performed with the software
SPSS 13.0 for Windows (SPSS, Inc., Chicago, IL, USA).
Results
Patient characteristics
All patients were followed up after initial treatment until
December 2012. The median follow-up period was
23 months (range 2–71 months).The patient characteris-
tics of TACE+RFA group and TACE alone group are sum-
marized in Table 1. There was no significant difference in
gender (P = 0.56), age (P = 0.99), AFP level (P = 0.61),
tumor size (P = 0.99), tumor number (P = 0.30) and Child-
Pugh grade (P = 0.98) between the two groups.
Technical effectiveness in TACE+RFA group
In TACE+RFA group, patients received median 2.0
(range 1–5) sessions of TACE treatment, followed by1-3
sessions of RFA. While in TACE alone group, patients
received median 3.0 (range: 1–9) sessions of TACE treat-
ment. Due to the presence of residual enhanced lesions
after treatment, 18 tumors in 9 patients received add-
itional sessions of RFA or TACE in TACE+RFA group. The
follow-up CT or MRI scan showed that 60 tumor nodules
in RFA+TACE group (Figures 1 and 2) and 108 tumor nod-
ules in TACE alone group were completely necrosed,
resulting in a technical effectiveness rate of 76.9% (60/78)
and 46.5% (108/232), respectively (P < 0.001).
Safety evaluation
Most patients in TACE+RFA group experienced post-
ablation syndrome, including fever, general fatigue and
abdominal pain that persisted for 1-5days after RFA. The
minor complications were asymptomatic self-limiting
pleural effusion (1/55, 1.8%) and local thermal skin in-
jury (1/55, 1.8%). A major complication was observed in
one patient (1/55, 1.8%), who developed gastrointestinal
bleeding within two week after RFA treatment. The most
common adverse events in TACE alone group were
abdominal pain, fever and nausea. However, these effects
were transient and relieved within 1–2 weeks after
TACE in most patients. Major complications included
sever liver dysfunction (2/156) and upper gastrointes-
tinal bleeding (2/156) within one week after TACE. The
major complication rate was 2.6%.
Local tumor control, tumor progression and associated
risk factors
Using mRECIST criteria, the post-treatment tumor
control rate was compared between the two groups. The
tumor control rate was defined as the proportion of
Table 1 Clinicopathalogical variables in TACE+RFA group
and TACE alone group
Variables TACE TACE+RFA P value
n = 156 n = 55
Gender
Male 138(88.5%) 47(85.4%) 0.56
Female 18(11.5%) 8(14.6%)
Age (years)
<=50 54(34.6%) 19(34.6%) 0.99
>50 102(65.4%) 36(66.4%)
HBsAg
Positive 118(75.6%) 36(65.5%) 0.14
Negative 38(24.4%) 19(34.5%)
Child-Pugh grade
A 136(87.2%) 48(87.3%) 0.98
B 20(12.8%) 7(12.7%)
AFP (ug/L)
Positive >20 108(69.2%) 36(65.5%) 0.61
Negative <=20 48(30.8%) 19(34.5%)
Tumor number
Single 115(73.7%) 35(66.2%) 0.30
Multiple 41(26.3%) 20(33.8%)
*Tumor size
Medial (range, cm) 6.0(5–8) 5.9(5–8) 0.99
AFP: α-fetoprotein.
HBsAg: hepatitis B surface antigen.
*Diameter of multiple tumors was calculated as the sum of the size of every
single tumor.
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response (PR), stable disease (SD) or progressive disease
(PD) at 6 month after treatment. In TACE+RFA group,
CR, PR, SD and PD were 60% (33/ 55), 10.9% (6/55) and
3.6% (2/55) and 25.5% (14/55) respectively versus 11.5%
(18/156), 20.5% (32/156), 22.4% (35/156) and 45.5% (71/
156) in TACE alone group. The total tumor control rateFigure 1 Contrast-enhanced CT images obtained in a patient with 6-c
hepatitis B-induced liver cirrhosis and a 6-cm solitary HCC tumor in the hep
arterial enhancement of the HCC lesion.(CR+PR+SD) was 74.5% in TACE+RFA group versus
54.5% in TACE alone group (P < 0.001).
Follow-up observation showed that the median time for
tumor progression was 6 months (range 1–28 months) in
TACE alone group versus 13 months (range 3–46 months)
in TACE+RFA group. The cumulative 1-, 3-, and 5-year
tumor progression rates in TACE alone group were 71.4%,
98.3% and 100%, respectively, which were significantly
higher than 36.0%, 81.6% and 90.8% in TACE+RFA group
(P < 0.001; Figure 3B). Univariate analysis showed that sin-
gle tumor and RFA treatment modality were correlated
with decreased tumor progression (P = 0.04 and P <
0.001). Multivariate analysis with Cox proportional
hazard model revealed that only RFA treatment was an
independent factor associated with decreased HR for
tumor progression (HR = 0.39, 95% CI: 0.27-0.56, P <
0.001) (Table 2).
Overall survival
The survival rate in patients who received the combin-
ation treatment was significantly higher than that in pa-
tients who received TACE alone (Figure 3A). The post-
treatment 1-, 3- and 5-year cumulative overall survival
was 89.8%, 61.1% and 37.4% respectively in TACE+RFA
group versus 67.2%, 36.6% and 16.5% in TACE alone
group. (P = 0.01). The median survival time was 19 months
(range 4–66 months) in TACE+RFA versus 11 months
(range 2–47 months) in TACE alone group. Univariate
analysis showed that RFA treatment (P = 0.01), along with
Child-Pugh grade (P = 0.04) displayed relevance to over-
all survival. Multivariate analysis with Cox proportional
hazard model showed that RFA treatment (HR = 0.51,
95% CI: 0.31-0.86, P = 0.01) was the only independent
factor for long-term survival (Table 2).
Subgroup analysis for stratification with tumor size
and number
The present study included HCC patients either with a
single tumor (size: 5-8 cm) or with multiple tumors (n ≤m single HCC before TACE treatment. (A-C) show a patient with
atic segment VI. The contrast-enhanced CT scan before TACE revealed
Figure 2 Radiofrequency ablation after transarterial chemoembolization was performed on the same patient with 6-cm HCC after
initial TACE treatment. (A) CT scan after TACE treatment shows lipiodol uptake in the central aspect of the lesion. (B) Contrast-enhanced MRI
scan at 4 weeks after RFA shows complete tumor necrosis without arterial enhancement within the lesion. (C) Contrast-enhanced MRI scan at
6 months after combination treatment shows no tumor recurrence in the liver.
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ber is an important factor of local tumor control in RFA
therapy and different tumor size or tumor number may
result in differences in local tumor control and affect
survival of HCC patients, we therefore analyzed the dif-
ferences in tumor control and overall survival between
the two subgroups (single-tumor group vs. multi-tumor
group). Although the local control rate of the multi-tumor
group was slightly higher than that of the single-tumor
group (15/20, 75.0% vs. 26/35, 74.3%), the difference did
not reach statistical significance (P = 0.51). Likewise, no
significant difference in 1-, 3-, and 5-year tumor progres-
sion rate was observed between the single-tumor group
and multi-tumor group (33.9%, 83.7% and 89.1% vs.
38.7%, 77.7% and 91.6%; P = 0.75), nor was there signifi-
cant difference in overall survival (89.7%, 59.8% and 36.0%
vs. 89.5%, 63.8% and 38.2%; P = 0.57).
Discussion
The combined use of TACE and RFA is a common
practice in the treatment of small HCC tumors. However,
whether this combination approach is more effective than
TACE alone in the treatment of patients with intermediateFigure 3 Overall survival rate (A) and tumor progression rate (B) of pstage HCC is unclear. In the present study, we compared
the treatment benefits between TACE+RFA and TACE
alone in 211 patients diagnosed with intermediate stage
HCC potentially amenable to RFA (single nodule with
diameter 5-8 cm; 2 ~ 5 multiple nodules with diameter less
than 5 cm). The results indicate TACE combined with
RFA delays tumor progression and prolongs overall sur-
vival in patients with intermediate stage HCC.
The therapeutic effect of TACE+RFA has been de-
scribed in several reports. Buscarini et al. [22] reported
that the combined use of RFA and TACE increased the
volume of coagulation necrosis in 14 HCC patients
(mean diameter 5.2 cm). In a multicenter clinical trial,
Lencioni et al. [23] reported successful ablation of HCC
tumors (range 3.5–8.5 cm) in 51 (82%) of the 62 HCC
patients treated with TACE and RFA. In accordance with
these previous studies, we reported a successful ablation
rate of 76.9% in BCLC stage B HCC lesions. Not a few
studies [24,25] have demonstrated that combined use of
RFA and TACE is safe, with a relatively low major compli-
cation rate. Similar to previous studies, we also found that
the patients were able to tolerate TACE+RFA treatment
with no death-related event occurring in our group ofatients in TACE+RFA group and TACE alone group.





Univariate Multivariate Univariate Multivariate
P P value HR 95% CI P P value HR 95% CI 95% CI
Gender (female vs. male) 0.37 NS 0.30 NS
Age, years (<50 vs. ≥50) 0.92 NS 0.18 NS
HBV (no vs. yes) 0.17 NS 0.52 NS
AFP ug/L (≤20 vs. >20) 0.11 NS 0.44 NS
Child-Pugh grade (A vs. B) 0.23 NS 0.04 NS
Tumor number (single vs. multiple) 0.04 NS 0.71 NS
RFA treatment <0.001 <0.001 0.39 0.27-0.56 0.01 0.01 0.51 0.31-0.86
AFP: alpha-fetoprotein; HBV: hepatitis B virus; CI: confidential interval; HR: hazard ratio.
NS: not significant; OS: overall survival; TTP: time to progression; RFA: radiofrenquency ablation.
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both TACE+RFA and TACE alone groups (1.6% vs. 2.8%).
According to the consensus of RFA guideline, RFA is
generally considered as an alternative treatment to par-
tial hepatectomy for early small HCC tumors (≤5 cm),
especially for patients with impaired liver function.
Without combination therapy, RFA alone should not be
indicated in HCC tumors larger than 5 cm, because it is
difficult for RFA alone to achieve complete ablation and
favorable local tumor control in large tumors [26]. How-
ever, serving as a downstage treatment before RFA,
TACE can reduce tumor burden by chemoembolization
and increase the ablation rates of large tumors in a
combination therapy. It also targets undetected satellite
lesions surrounding the main tumor, labels the range of
tumor, provides guidance in RFA procedure, thus in-
creasing the possibility of complete ablation of the main
tumor as well as its surrounding satellite lesions. We
therefore anticipated that TACE+RFA combination would
provide a favorable local control in the treatment of BCLC
stage B HCC. Indeed, we found that the total tumor con-
trol rate was 74.5% in TACE+RFA group, which is signifi-
cantly higher than 54.5% in TACE alone group (P < 0.001).
The cumulative 1-, 3- and 5-year tumor progression rate
in TACE+RFA group was 36.0%, 81.6% and 90.8% respect-
ively, which are significantly lower than 71.4%, 98.3% and
100% in TACE alone group (P < 0.001). Our subsequent
subgroup analysis showed that combined RFA seemed to
have the same effect on local tumor control in patients
with either solitary tumor (size: 5-8 cm) or multiple tu-
mors (n ≤ 5, size ≤5 cm). In addition, multivariate analysis
showed that it was combined RFA treatment (HR = 0.51,
95% CI: 0.31-0.86, P = 0.01) rather the tumor size or tumor
number that was the only independent factor for tumor
progression. All these results indicate that the combin-
ation regime offers better efficacy of local thermal abla-
tion and extends the indication of conventional RFAablation with respect to the tumor size and number,
thereby facilitating favorable local control of BCLC
stage B HCC tumors.
It was also found in our study that the combination
therapy significantly prolonged overall survival of pa-
tients with intermediate stage HCC. The postoperative
1-, 3- and 5-year cumulative OS was 89.8%, 61.1% and
37.4% respectively in RFA+TACE group versus 67.2%,
36.6% and 16.5% in TACE alone group. The median sur-
vival time of patients undergoing combination therapy
was significantly longer than that of patients receiving
TACE alone (19 months vs. 11 months, P = 0.01). These
results are not surprising. TACE combined with RFA pro-
vides a better local control and a lower tumor progression
rate as compared with TACE alone therapy, thus contrib-
uting to a favorable survival outcome. In addition, com-
bined TACE and RFA could overcome tumor burdens
more effectively in large HCC tumors and avoid repeated
TACE treatments that may damage liver function, thus
providing significant survival benefits.
As a regional interventional therapy, RFA has led to a
major breakthrough in the management of HCC. Real-
time virtual sonography and overlap procedures increase
the number of patients eligible for RFA treatment, espe-
cially for large HCC tumors. However, when considering
the treatment guideline for unresectable HCC, most pa-
tients would be excluded from radical treatment owing
to non-early stage tumors. Thus, clinicians may not be
able to avoid the selection of palliative TACE instead of
RFA or operation. Our series has provided encouraging
evidence of the efficacy of TACE and RFA combination in
the treatment of intermediate stage HCC patients. We sug-
gest that subsequent tumor ablation should be considered
in patients with residual tumors that are potentially amen-
able to RFA after TACE treatment. In other words, patients
with intermediate stage HCC should be examined by ultra-
sound or contrast ultrasound after TACE treatment to
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quent RFA. For example, patients with single HCC nodules
larger than 5 cm could be initially treated with TACE, and
then with RFA when the tumor is shrunken and can be
ablated by using RFA, since such combination therapy can
confer a favorable prognosis compared with monotherapy.
Our study has several limitations. First, this study was
retrospectively performed and was not randomized in de-
sign. Second, all planning RFA procedures were performed
in a single institution. Therefore, the results obtained in
this study might be influenced by both the experience of
the physician and the patient population. Finally, 73% of
our patients had a history of positive HBV, which differs
greatly from studies in the United States, Europe, and
Japan. Thus, the treatment modality needs further investi-
gation in HCC patients from these areas.
Conclusions
In summary, our study demonstrates that combination
therapy with TACE and RFA is an effective and safe treat-
ment that may delay tumor progression and prolong overall
survival in patients with BCLC B hepatocellular carcinoma.
On the basis of our findings, this newly developed combin-
ation therapy is likely to be a promising therapeutic option
for intermediate stage HCC. Future prospective studies are
warranted to further confirm the benefits of this combin-
ation therapy.
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